500 SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection

• Filip Janku,
• Jason Luke,
• Sarina Piha-Paul,
• Karl Lewis,
• James Strauss,
• Mary Varterasian,
• Anna Sokolovska,
• Richard Riese,
• Michael Armstrong,
• Claire Verschraegen,
• Aoife Brennan

Affiliations

Filip Janku

Department of Investigational Cancer Therapeutics, University of Texas at MD Anderson Cancer Center, Houston, Texas, USA

Jason Luke

1University of Iowa, Iowa City, IA, USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Karl Lewis

6University of Colorado, Aurora, CO, USA

James Strauss

2Mary Crowley Cancer Research Center, Dallas, TX, USA

Mary Varterasian

3BioMed Valley Discoveries Inc., Kansas City, MO, USA

Anna Sokolovska

2Synlogic Inc., Boston, MA, USA

Richard Riese

11 Pfizer Inc, Groton, Connecticut, USA

Michael Armstrong

6IQVIA Biotech, Durham, NC, USA

Claire Verschraegen

5Ohio State University, Columbus, OH, USA

Aoife Brennan

1Synlogic Inc, Cambridge, MA, USA